Pediatric cardiologists can make a significant impact on global health trends by looking for early warning signs of CVD in their patients and collaborating with other physicians.

Researchers tracked real-world data from nearly 60,000 Medicare patients, highlighting the benefits of weekly injections of semaglutide. 

An oral version of the popular GLP-1 drug was associated with multiple benefits, including considerable improvements in BMI and waist circumference. Previous research found that it reduces certain heart risks in patients with type 2 diabetes.

The agency emphasized that many over-the-counter technologies marketed for this purpose have not been properly evaluated. 

The FDA has categorized this as a Class I recall. If patients update their phone or watch apps as needed, they can continue to use these devices like normal.

Diets that prioritize plant-based foods are associated with several health benefits, according to a new study of more than 3.4 million adults. Such diets also show potential to reduce greenhouse gas emissions.

"We can start helping people right now, and it would be meaningful if we can raise more awareness to reduce the burden of CVD," explained Katherine Wilemon, founder and CEO of the Family Heart Foundation. 

Eli Lilly and Company is back with even more positive data on orforglipron, its oral GLP-1 receptor agonist. The company says it is "moving with urgency" toward gaining key regulatory approvals and getting the drug in the hands of patients.